Norges Bank
CMTA

Norges Bank’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Norges Bank’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50,000
Closed -$949K – 2180
2017
Q4 		$949K Hold
50,000
– – ﹤0.01% 2066
2017
Q3 		$844K Buy
+50,000
New +$817K ﹤0.01% 2075

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Norges Bank's CMTA Position: Q1 2018 in Review

Norges Bank sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q1 2018, closing a stake of 50,000 shares — an estimated $949K sold.

Norges Bank first reported a position in CMTA in Q3 2017 and held it in 2 quarters. The position peaked at $949K in Q4 2017. 38 funds tracked by Wall St. Rank hold CMTA as of Q1 2018.

  • Norges Bank reported no remaining Clementia Pharmaceuticals Inc. position as of Q1 2018 after selling out during the quarter.
  • Norges Bank sold 50,000 Clementia Pharmaceuticals Inc. shares in Q1 2018, an estimated $949K.
  • Norges Bank first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 2 quarters.
  • Norges Bank's Clementia Pharmaceuticals Inc. position peaked at $949K in Q4 2017.
  • 38 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q1 2018.

Based on Norges Bank's 13F filing for Q1 2018, filed 9 May 2018.